本拉利祖马布可以预防慢性阻塞性肺部疾病患者的复发性恶化:后期分析
Dave Singh1, Gerard J Criner2, Alvar Agustí3
1Manchester University NHS Foundation Hospital Trust, the University of Manchester, Manchester, UK.
概括
贝纳利祖马布可以预防一些慢性阻塞性肺病 (COPD) 患者的复发性恶化,这些患者具有高胆固醇细胞计数. 这种生物疗法对高风险的慢性肺炎患者群体具有前景,需要进一步研究.
科学领域:
- 肺部病理学 肺部病理学
- 临床试验 临床试验
- 免疫学 免疫学 免疫学
背景情况:
- 慢性阻塞性肺病 (COPD) 恶化给人带来很大的负担.
- 预防复发性COPD恶化仍然是一个至关重要的未满足的需求.
- 目前的治疗方法往往无法预防重症慢性肺炎的频繁恶化.
研究的目的:
- 探索本拉利祖马布在预防特定患者亚组中COPD恶化方面的疗效.
- 为了确定对本拉利祖马布治疗COPD恶化的潜在响应者.
- 分析恶化后的30天和90天期间的恶化模式.
主要方法:
- 对 GALATHEA 和 TERRANOVA 临床试验的特点分析.
- 包括患有频繁COPD恶化患者,尽管优化了三重疗法.
- 在已识别的响应人群中评估本拉利祖马布补充治疗的疗效.
主要成果:
- 贝纳利祖马布在整个研究群体中没有显著降低年度恶化率.
- 一项探索性分析确定了一个响应子组,其特点是血液中高血红蛋白细胞计数.
- 在这个子组中,本拉利祖马布治疗在易受伤害的30日和90天后恶化期内预防了复发性COPD恶化.
结论:
- 针对性生物疗法,如本拉利祖马布,可能有利于特定高风险的COPD人群.
- 血液中高血红蛋白细胞计数可以确定本拉利祖马布治疗的潜在响应者.
- 需要进一步的研究来证实本拉利祖马布在选择的患者中对COPD恶化的益处.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
346
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
346
01:17Drugs Used in Lower Respiratory Disorders: Overview
489
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
489
01:19Antiasthma Drugs: Leukotriene Modifiers
361
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
361
01:26COPD: Management Using Bronchodilators and Corticosteroids
244
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
244
01:22Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
307
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
307